A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

CD22 is currently evaluated as a target-antigen for the treatment of B-cell malignancies using chimeric antigen receptor (CAR)-engineered T-cells or monoclonal antibodies (mAbs). CAR- and mAbs-based immunotherapies have been successfully applied targeting other antigens, however, occurrence of refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahn, Lorenz, Hagedoorn, Renate S., van der Steen, Dirk M., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342099/
https://www.ncbi.nlm.nih.gov/pubmed/27689397
http://dx.doi.org/10.18632/oncotarget.12247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342099/
https://www.ncbi.nlm.nih.gov/pubmed/27689397
http://dx.doi.org/10.18632/oncotarget.12247

Ejemplares similares